Darbepoetin Alfa
Darbepoetin alfa, recombinant human erythropoiesis-stimulating protein
165 Amino Acids · MW: ≈37,000 Da
Amino Acids
165
Molecular Weight
≈37,000 Da
Half-life
~21 h IV; ~49 h SC
Research Score
4.7
Studies
210
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is Darbepoetin Alfa?
Darbepoetin alfa is a longer-acting erythropoiesis-stimulating protein derived from erythropoietin with additional glycosylation. Its performance relevance is indirect, via sustained hemoglobin and oxygen transport rather than direct muscle anabolism.
Key Benefits & Mechanisms
longer-acting erythropoiesis
stable hemoglobin
increased oxygen delivery
may improve aerobic capacity
Research Summary
Clinical studies show durable hemoglobin correction with less frequent dosing than epoetin alfa. The endurance benefit, where present, would come from improved oxygen-carrying capacity rather than a direct ergogenic pathway.
Related Peptides
FS315
Follistatin-315 (FS315)
The circulating major isoform of follistatin that binds activins and can modulate myostatin signaling. It is widely used in research because it is the more common endogenous secreted form in human plasma.
Muscle & PerformanceACE-031
ACE-031 (soluble activin receptor type IIB-Fc)
A recombinant decoy receptor fusion protein that traps myostatin and related ligands such as activins. It was developed to promote skeletal muscle growth and counteract wasting.
Muscle & PerformanceBYM338
Bimagrumab (BYM338)
A human monoclonal antibody against activin type II receptors that blocks myostatin/activin signaling at the receptor level. It has been studied for sarcopenia, obesity with muscle preservation, and several wasting conditions.
Muscle & PerformanceREGN1033
Trevogrumab (REGN1033)
A human monoclonal antibody that neutralizes myostatin, the key negative regulator of skeletal muscle growth. It has been evaluated for muscle loss states and as a body-composition modulator in combination regimens.
Muscle & Performance